Latest Breaking News On - Stefan riley - Page 2 : comparemela.com

Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of INZ-701 In Adults With ABCC6 Deficiency And ENPP1 Deficiency On April 8, 2024

Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of INZ-701 In Adults With ABCC6 Deficiency And ENPP1 Deficiency On April 8, 2024
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United arab emiratesUnited statesZulf mughalY joyce liaoInozyme pharmaMatt peraStefan rileyExchange commissionCompany or inozymeCorporate communicationsInternational numberCompany natural history studyInozyme pharma incNatural history studyStanford medicinePaediatric bone disorders

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –– Phase 1 tr.

United statesDouglasa trecoStefan rileyChristine obrienInozyme pharmaMatt peraSagar nigwekarEuropean calcified tissue society congressCorporate communicationsExchange commissionAmerican society of nephrologyCompany or inozymeKidney research centerInozyme pharma incDevelopment rd expensesPatient registry

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 06, 2024 Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal.

United statesStefan rileyMatt peraInozyme pharmaCompany or inozymeCorporate communicationsGlobenewswire incInozyme pharma incStock incentive planNasdaq listing rule

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –

United statesStefan rileyDouglasa trecoInozyme pharmaMatt peraPamerican society for boneDrug administrationInozyme pharma incDevelopment rd expensesAmerican society for nephrologyPaediatric committee of the european medicines agencyMineral researchCorporate communicationsAmerican society of nephrology kidney weekExchange commissionAmerican society

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 - Inozyme Pharma (NASDAQ:INZY)

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

United statesInozyme pharmaSagar nigwekarStefan rileyMatt peraResearch advances in boneDrug administrationInozyme pharma incEuropean calcified tissue society congressCorporate communicationsAmerican society of nephrologyKidney research centerExchange commissionMmsc coAmerican societyKidney week